Since Albright, [1] some 60 years ago, reported the beneficial effects of estrogens for decreasing urinary calcium excretion and suggested that these harmones might be useful in preventing postmenopausal osteoporosis, estrogen replacement therapy (ERT) has been consistently regarded as the first choice for prevention of trabecular and cortical bone loss in postmenopausal women [2] [3] [4] [5] . However, serious controversies remain over the cost/effectiveness of treating every woman at the time of menopause [6], the optimal timing for starting ERT [5], the minimal effective dose of ERT acting on bone [7] , and the duration of ERT needed to prevent osteoporotic fractures [8] . The effectiveness of ERT for preventing osteoporosis-related fractures is undisputed and requirements for marketing authorization for ERT products have lightened compared with current requests for other therapeutic medications developed in this field [9, 10] . However, although the skeletal benefits of ERT for preventing trabecular or cortical bone loss can hardly be challenged, one might be wary of published evidence that prolonged ERT use unequivocally reduces the risk of hip fracture. Controlled clinical trials and systematic reviews were located using Medline 1970-1999 and EMBASE 1980-1999. Since 1985 we have searched scientific journals on bone and bibliographies of review articles. All prospective controlled trials were included for evaluation of the effects of hormone replacement therapy (HRT) on bone loss. A total of 57 prospective controlled trials were identified, 46 of which were randomized clinical trials (RCTs) and 15 were double blinded. All clinical trials assessing the effects of HRT on fracture rates were considered. Two RCTs and one systematic review were identified [11] .
Since Albright, [1] some 60 years ago, reported the beneficial effects of estrogens for decreasing urinary calcium excretion and suggested that these harmones might be useful in preventing postmenopausal osteoporosis, estrogen replacement therapy (ERT) has been consistently regarded as the first choice for prevention of trabecular and cortical bone loss in postmenopausal women [2] [3] [4] [5] . However, serious controversies remain over the cost/effectiveness of treating every woman at the time of menopause [6] , the optimal timing for starting ERT [5] , the minimal effective dose of ERT acting on bone [7] , and the duration of ERT needed to prevent osteoporotic fractures [8] . The effectiveness of ERT for preventing osteoporosis-related fractures is undisputed and requirements for marketing authorization for ERT products have lightened compared with current requests for other therapeutic medications developed in this field [9, 10] . However, although the skeletal benefits of ERT for preventing trabecular or cortical bone loss can hardly be challenged, one might be wary of published evidence that prolonged ERT use unequivocally reduces the risk of hip fracture. Controlled clinical trials and systematic reviews were located using Medline 1970 -1999 and EMBASE 1980 -1999 . Since 1985 we have searched scientific journals on bone and bibliographies of review articles. All prospective controlled trials were included for evaluation of the effects of hormone replacement therapy (HRT) on bone loss. A total of 57 prospective controlled trials were identified, 46 of which were randomized clinical trials (RCTs) and 15 were double blinded. All clinical trials assessing the effects of HRT on fracture rates were considered. Two RCTs and one systematic review were identified [11] .
In the 46 randomized controlled trials comparing estrogen (with or without progestins) (HRT) with placebo or calcium on bone loss prevention, the study population varied from 14 to 875 women and the duration was from .5 to 10 years. In general, they drew similar conclusions, i.e, that estrogen intervention reduces the rate of postmenopausal bone loss at trabecular and cortical sites. An early doubleblind trial [12] reported the preventive effects of HRT on cortical (metacarpal) bone loss for up to 10 years. More recent double-blind, placebo-controlled, randomized clinical trials confirmed these findings for oral [13] , percutaneous [14, 15] , or transdermal [16] estrogens at the spine [13, 14, 16] , the forearm [16] , and/or the hip [13, 16] for up to 3 years. Two prospective open studies [17, 18] showed similar results for estrogen implants after 1 year. When standardized for technique used for bone mineral density (BMD) assessment, the magnitude of the point estimate differences between the HRT and the control group varied greatly from one study to another, depending upon the dose of HRT used (dose-related effect on bone mass in most randomized controlled trials), skeletal site measured (effect more pronounced on trabecular bone), age of the population (effect more pronounced early after the menopause) [19] , and the nature of the combined progestins (trivial effect of progestins except for norethisterone acetate that synergistically acts with estrogens to increase bone mass) [20, 21] . Though evidence that HRT prevents postmenopausal bone loss is strong, studies providing direct demonstration of a reduction in fracture rates as a consequence of HRT intake are more scarce and subject to controversy.
No systematic review has evaluated the effect of HRT on vertebral fracture rates. In one single, double-blind, randomized, controlled trial [16] , 75 postmenopausal women (47-75 years) with one or more prevalent vertebral fractures, were randomized to transdermal HRT (17␤ estradiol and oral medroxyprogesterone acetate) or placebo. After 12 months, 8 new fractures occurred in 7 women in the estrogen group whereas 20 occurred in 12 women in the placebo group, yielding a lower vertebral fracture rate in the estrogen group (RR ‫ס‬ 0.39, 95% CI ‫ס‬ 0.16-0.95). However, these results were based on the number of fractures per person-years (23 versus 58/100). When expressing the results as the number of patients having experienced a new vertebral fracture, as recommended in regulatory guidelines [10] the difference between 7 women suffering fractures in HRT and 12 in placebo is no longer statistically significant. A group of 100 postmenopausal women who had previously taken part in a randomized controlled trial were reviewed afer a median follow-up period of 9 years [22] . An indirect measurement (total spine score) of the prevalence of vertebral fracture revealed a significant (P < 0.01) difference in favor of estrogen users compared with placebo-treated patients, whereas other indices (absolute difference in anterior height and ratio of central vertebral height to anterior height of vertebrae) failed to achieve significance. In a case-control study published first as a retrospective survey of 490 women followed for an average of 17.6 years [23] , and later as the same cohort followed for an additional average of 8 years [24] , RR for vertebral and wrist fractures in estrogen users were 0.57 (95% CI ‫ס‬ 0.41-0.80) and 0.55 (95% CI ‫ס‬ 0.32-0.92), respectively.
For nonvertebral fractures, one systematic review of the literature published between 1970 and 1991 is available [25] . From the analysis 11 epidemiological studies (6 casecontrol and 5 cohort), the authors concluded that the pooled estimates of the relative risk for hip fracture comparing ever-users of estrogen with nonusers was 0.75 (95% CI ‫ס‬ 0.68-0.84). Since that time, two randomized controlled trials and five epidemiological studies have evaluated the effect of HRT on nonspinal osteoporotic fractures. A doubleblind, placebo-controlled, randomized trial was primarily designed to evaluate the effect of HRT on secondary prevention of coronary heart disease, assessment of fractures being only a secondary endpoint. After following 2763 postmenopausal women younger than 90 years of age for an average of 4.1 years, the authors found no difference between estrogen and placebo users for hip fracture (12 in the HRT group versus 11 in the placebo group) (RR ‫ס‬ 1.10: 95% CI ‫ס‬ 0.49-2.50) or any fracture (RR ‫ס‬ 0.95; 95% CI ‫ס‬ 0.75-1.21) [26] .
One can argue that in this study, fracture reduction was not the primary endpoint, the overall number of hip fracture was too low to draw significant conclusions, the study was not powered to assess this outcome, the study population was not selected on the basis of risk factors for osteoporosis, and that some doubts remain regarding fracture data collection. However, the most worrisome fact is not the absence of significant reduction in hip fractures but that the absolute number of hip fractures did not even show a trend in favor of HRT users.
From an open, randomized, controlled trial [27] having included 464 postmenopausal women, 368 were followed for a mean duration of 4.3 years. The estimate risk of new symptomatic nonvertebral fractures among women treated with HRT alone was 0.29 (95% CI ‫ס‬ 0.10-0.90) whereas it was nonsignificant in women receiving a combination of HRT and vitamin D (RR ‫ס‬ 0.44; 95% CI ‫ס‬ 0.17-1.15) compared with the placebo group (adjusted by femoral density and previous fractures).
From the five epidemiological studies, three were prospective cohort studies and two retrospective, case-control trials. In the DUBBO study [28] (1091 women), mean age 70 years, followed prospectively between 1989 and 1993, the incidence of atraumatic fractures (any site) among nonestrogen users was not significantly different than that of estrogen users (OR ‫ס‬ 1.06; 95% CI ‫ס‬ 0.94-1.16).
The follow-up of the Framingham study through examination 19 (2873 women originally recruited and 948 attending examination 19) [29] also revealed that current estrogen intake was not significantly linked to a reduction in hip fracture (OR ‫ס‬ 0.38; 95% CI ‫ס‬ 0.12-1.21).
More recently, the analysis of the "Study of Osteoporotic Fracture" (SOF) [15] (9704 women, 65 years of age or older, followed during an average of 4.6 years) concluded that current estrogen use was associated with a decrease in the risk for wrist fracture (RR ‫ס‬ 0.39; 95% CI ‫ס‬ 0.24-0.64) and for all nonspinal fractures (RR ‫ס‬ 0.66; 95% CI ‫ס‬ 0.54-0.80) when compared with nonestrogen users. The risk for hip fracture was not significantly different between current users and never-users (RR ‫ס‬ 0.60; 95% CI ‫ס‬ 0.36-1.02). However, current users who had started HRT within 5 years of menopause had a decreased risk of hip fracture (RR ‫ס‬ 0.29; 95% CI ‫ס‬ 0.09-0.92), wrist fracture (RR ‫ס‬ 0.29; 95% CI ‫ס‬ 0.13-0.68), and all nonspinal fractures (RR ‫ס‬ 0.50; 95% CI ‫ס‬ 0.36-0.70). The authors of this prospective cohort study concluded that for protection against fracture, estrogen should be initiated soon after the menopause and continued indefinitely [8] .
The two retrospective case-control studies are the MEDOS study [30] (2086 women with hip fractures and 3582 controls) and the Swedish hip fracture study [31, 32] (1328 incident cases with hip fracture and 3312 randomly selected controls). In the MEDOS study, the relative risk of hip fracture in women taking estrogen was 0.55 (95% CI ‫ס‬ 0.31-0.85). In the Swedish study, current estrogen users were significantly protected against hip fracture (OR + 0.35; 95% CI ‫ס‬ 0.24-0.53) whereas no significant difference was observed for former users (OR ‫ס‬ 0.76; 95% CI ‫ס‬ 0.57-1.01). The protective effect of estrogens was substantially diminished after 5 years of HRT cessation (−7% to −48%). In view of these results, the problem of long-term compliance of postmenopausal women with HRT becomes even more critical.
Several cross-sectional or retrospective studies have addressed this issue in daily practice. From the SOF cohort (9704 non-black women aged 65 and older), 17.1% of the women between 65 and 69 years reported current use of oral estrogens but only 3.9% of women 85 years and older were currently using oral estrogens [33] . From the database of the Kayser Foundation Health Plan [39] (1532 women >45 years old who initially filled index prescription for 0.625 mg/day of conjugated estrogens), the probability of continu-ing HRT for 36 months varied between 0.19 (continuous combined estrogens-progestin therapy) and 0.24 (cyclic combination therapy adding progestin to estrogens) [40] . Even worse results reported from a survey of five group practices of Dutch general practitioners (1689 women aged 45-60 years) where the mean duration of HRT use (main indication for prescription was menopausal complaints) was 7 months and only 8% of the women remained on HRT for more than 2 years (41). In the United Kingdom (400 postmenopausal women aged 40-69 years), prescription of HRT because of increased risk for osteoporosis resulted in 40% of women with low BMD not taking HRT 8 months after referral (42). In all surveys, the main reasons for stopping HRT were anxiety over possible side-effects, especially breast cancer, weight gain, and bleeding.
The purpose of the present editorial is not to challenge the overall benefit of HRT in postmenopausal women. Extraskeletal benefits of ERT or HRT have been extensively discussed elsewhere. (see 43). Our concern is the preferential treatment given to HRT products compared with other currently developed medications, where evidence of an antifracture efficacy at the level of the spine or hip is requested. We are convinced that if any new chemical entity other than the one currently available for ERT or HRT, i.e., bisphosphonates, calcitonin, or SERMS, were filing for marketing authorization with such a limited demonstration of antifracture efficacy it would most likely be poorly received both by regulatory authorities and the scientific community.
We agree that initiating a double-blind, placebocontrolled prospective study evaluating the antifracture benefit of HRT on the spine or the hip would not only be a methodological challenge but also somewhat unethical in view of the extraskeletal benefits of HRT. However, in view of appropriate published studies demonstrating the antifracture efficacy of antiosteoporotic drugs, an open prospective equivalent trial comparing HRT to these drugs, with spine or hip fracture reduction as a primary endpoint, would scientifically validate the currently widespread dogma that HRT should be used for life by postmenopausal women to prevent osteoporosis-related fractures.
